The National Australian HCV Point-of-Care Testing Program - HCV Antibody Testing Minimal Dataset - Trial NCT05713136
Access comprehensive clinical trial information for NCT05713136 through Pure Global AI's free database. This phase not specified trial is sponsored by Kirby Institute and is currently Not yet recruiting. The study focuses on Hepatitis C. Target enrollment is 40000 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Kirby Institute
Timeline & Enrollment
N/A
Mar 01, 2023
Dec 31, 2025
Primary Outcome
To evaluate the proportion of HCV infected (HCV RNA quantifiable) participants who initiate HCV treatment at 12 weeks following finger-stick point-of-care HCV RNA testing.
Summary
This is an observational cohort study. Participants will be recruited from settings that
 provide services to people with a risk factor for the acquisition of HCV infection.
 Participants will attend a single visit to have HCV point-of-care testing. Participants who
 have not previously received HCV treatment will have a point-of-care HCV antibody test,
 followed by reflex point-of-care HCV RNA test if positive. Those who have a history of HCV
 treatment will proceed straight to point-of-care HCV RNA testing. Participants will not
 receive treatment as a part of this study. Participants who are HCV RNA positive will receive
 treatment via standard of care. The purpose of this study is to look at the effect of
 finger-stick point-of-care hepatitis C testing, to see if it increases the number of tests,
 diagnoses, and treatments for people with a risk factor of having hepatitis C in Australia.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05713136
Device Trial